A compound of the formula: wherein A is a five-membered heteroaryl ring which is optionally substituted with halo, cyano, R 5 , R 6 , (C=O)N(R 5 ) 2 , NR 5 (C=O)N(R 5 ) 2 , (C=O)R 6 or (C 1-3 alkyl)O(C=O)R 4 ; R 1 is phenyl, bicyclic aryl, tricyclic aryl or heteroaryl, which may be monocyclic, bicyclic or tricyclic, wherein said phenyl and heteroaryl groups are optionally substituted with one to four groups independently selected from the group consisting of halo, oxo, cyano, C 2-3 alkenyl, R 5 , R 6 , OR 5 , N(R 5 ) 2 , (C=O)NHR 6 , NR 5 (C=O)N(R 5 ) 2 , NR 5 (C=NR 5 )N(R 5 ) 2 , SO 2 R 5 , SO 2 N(R 5 ) 2 , NR 5 SO 2 R 5 , and NR 5 SO 2 N(R 5 ) 2 ; R 2 is NH(C=O)R 6 or NH(C=O)(C 1-3 alkyl)R 6 ; R 3 is selected from hydrogen, C 1-6 alkyl or CH 2 OR 5 ; R 4 is C 1-6 alkyl, or C 3-6 cycloalkyl, which is optionally substituted with one to three substituents independently selected from the group consisting of halo and hydroxyl, or C 3-6 cycloalkyl; each R 5 is independently hydrogen, cyano, or C 1-6 alkyl, which is optionally substituted with NH 2 , N(CH 3 ) 2 , NH(CH 3 ) 2 , N(CH 2 CH 3 ) 2 , or one to three halo; R 6 is selected from the group consisting of azaspirobicyclooctanecyclopropanyl, azaspirohepatnyl, azaspirohexanyl, azaspirononanyl, azaspirooctanyl, cyclopropyl, diazaspirooctanyl, dihydropyrroloindolyl, dihydroethanoquinolinyl, isoxazolyl, oxadiazaspirodecenyl, oxaspirooctanyl, spirooctanyl, spirocyclohexanefuropyridinyl, tetrahydrocyclopentaindolyl, and tetrahydropyranyl, wherein said groups are optionally substituted with one or two groups independently selected from the group consisting of halo, oxo, R 5 , OR 5 , (C=O)N(R 5 ) 2 , C 2-3 alkenyl, benzyl, benzyl-OR 5 , CH 2 (C 3-6 cycloalkyl), CH 2 (heteroaryl), heteroaryl and C 3-6 cycloalkyl; or a pharmaceutically acceptable salt thereof. wherein A is a five-membered heteroaryl ring which is optionally substituted with halo, cyano, R 5 , R 6 , (C=O)N(R 5 ) 2 , NR 5 (C=O)N(R 5 ) 2 , (C=O)R 6 or (C 1-3 alkyl)O(C=O)R 4 ; R 1 is phenyl, bicyclic aryl, tricyclic aryl or heteroaryl, which may be monocyclic, bicyclic or tricyclic, wherein said phenyl and heteroaryl groups are optionally substituted with one to four groups independently selected from the group consisting of halo, oxo, cyano, C 2-3 alkenyl, R 5 , R 6 , OR 5 , N(R 5 ) 2 , (C=O)NHR 6 , NR 5 (C=O)N(R 5 ) 2 , NR 5 (C=NR 5 )N(R 5 ) 2 , SO 2 R 5 , SO 2 N(R 5 ) 2 , NR 5 SO 2 R 5 , and NR 5 SO 2 N(R 5 ) 2 ; R 2 is NH(C=O)R 6 or NH(C=O)(C 1-3 alkyl)R 6 ; R 3 is selected from hydrogen, C 1-6 alkyl or CH 2 OR 5 ; R 4 is C 1-6 alkyl, or C 3-6 cycloalkyl, which is optionally substituted with one to three substituents independently selected from the group consisting of halo and hydroxyl, or C 3-6 cycloalkyl; each R 5 is independently hydrogen, cyano, or C 1-6 alkyl, which is optionally substituted with NH 2 , N(CH 3 ) 2 , NH(CH 3 ) 2 , N(CH 2 CH 3 ) 2 , or one to three halo; R 6 is selected from the group consisting of azaspirobicyclooctanecyclopropanyl, azaspirohepatnyl, azaspirohexanyl, azaspirononanyl, azaspirooctanyl, cyclopropyl, diazaspirooctanyl, dihydropyrroloindolyl, dihydroethanoquinolinyl, isoxazolyl, oxadiazaspirodecenyl, oxaspirooctanyl, spirooctanyl, spirocyclohexanefuropyridinyl, tetrahydrocyclopentaindolyl, and tetrahydropyranyl, wherein said groups are optionally substituted with one or two groups independently selected from the group consisting of halo, oxo, R 5 , OR 5 , (C=O)N(R 5 ) 2 , C 2-3 alkenyl, benzyl, benzyl-OR 5 , CH 2 (C 3-6 cycloalkyl), CH 2 (heteroaryl), heteroaryl and C 3-6 cycloalkyl; or a pharmaceutically acceptable salt thereof. <EOS>